How Investors May Respond To 10x Genomics (TXG) Patent Invalidation in Advanced Genomics Tools

Endpoints NewsNovo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial exec

BioPharma DivePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?

Lonza NewsStipple Bio taps Lonza platform to advance ADC pipeline - The Pharma Letter

CellSingle-cell mapping of regulatory DNA-protein interactions

CellPlasma signals of lung tumor promotion for molecular cancer prevention

CellDeep learning of functional perturbations from condensate morphology

FierceBiotechAt first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from experts

Lonza NewsStipple Bio taps Lonza platform to advance ADC pipeline - The Pharma Letter

10x Genomics Blog10x Genomics Stock On Fire: Up 41% With 8-Day Winning Streak - Trefis

LabiotechEpisode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media

Lonza NewsLonza and Stipple Bio partner to advance next-generation precision oncology ADC therapies - Indian Pharma Post

Eli LillyGilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSN